Avenzo Therapeutics Announces Oral Presentation of Phase 1 Data for VBC103 (AVZO-103), a Potentially Differentiated Nectin-4/TROP2 Bispecific Antibody-Drug Conjugate, by Partner VelaVigo at ESMO Asia Congress 2026

Posted on by sHq_LoGiNz

SAN DIEGO–(BUSINESS WIRE)–Avenzo Therapeutics Announces Oral Presentation of Phase 1 Data for VBC103 (AVZO-103), a Potentially Differentiated Nectin-4/TROP2 BsADC, by VelaVigo

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.